1 Yu Y, Yang G, Huang H, et al. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. J Exp Clin Cancer Res. 2021; 40: 8.
2 Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med. 2016; 280: 97-113.
3 Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015; 15: 540-555.
4 Shimomura O, Oda T, Tateno H, et al. A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin–Drug Conjugate (LDC). Molecular Cancer Therapeutics. 2018; 17: 183-195.
5 Hasehira K, Furuta T, Shimomura O, Asada M, Oda T, Tateno H. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models. Biochem Biophys Res Commun. 2020.
6 Tateno H, Toyota M, Saito S, et al. Glycome diagnosis of human induced pluripotent stem cells using lectin microarray. J Biol Chem. 2011; 286: 20345-20353.
7 Tateno H, Matsushima A, Hiemori K, et al. Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN. Stem Cells Transl Med. 2013; 2: 265-273
8 Tateno H, Saito S. Engineering of a Potent Recombinant Lectin- Toxin Fusion Protein to Eliminate Human Pluripotent Stem Cells. Molecules. 2017; 22.
9 Mawaribuchi S, Onuma Y, Aiki Y, et al. The rBC2LCN-positive subpopulation of PC-3cells exhibits cancer stem-like properties. Biochem Biophys Res Commun. 2019; 515: 176-182.
10 Kitaguchi D, Oda T, Enomoto T, et al. Lectin drug conjugate therapy for colorectal cancer. Cancer Sci. 2020; 111: 4548-4557.
11 Mawaribuchi S, Haramoto Y, Tateno H, Onuma Y, Aiki Y, Ito Y. rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma. FEBS Open Bio. 2020; 10: 1056-1064.
12 Liu JY, Jiang L, Liu JJ, et al. AEBP1 promotes epithelial- mesenchymal transition of gastric cancer cells by activating the NF-kappaB pathway and predicts poor outcome of the patients. Sci Rep. 2018; 8: 11955.
13 Liu L, Liu X, Dong Z, et al. N6-methyladenosine-related Genomic Targets are Altered in Breast Cancer Tissue and Associated with Poor Survival. J Cancer. 2019;10: 5447-5459.
14 Beauchemin N, Benchimol S, Cournoyer D, Fuks A, Stanners C P. Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen. Mol Cell Biol. 1987; 9: 3221-3230.
15 Hammarstrom S, Engvall E, Johansson BG, Svensson S, et al. Nature of the tumor associated determinant(s) of carcinoembryonic antigen. Proc Natl Acad Sci USA. 1975; 72: 1528-1532.
16 Yamashita K, Totani K, Kuroki M, Matsuoka Y, et al. Structural studies of the carbohydrate moieties of carcinoembryonic antigens. Cancer Res. 1987; 13: 3451-3450.
17 Chandrasekaran EV, Davila M, Nixon DW, Goldfarb M, et al. Isolation and structures of the oligosaccharide units of carcinoembryonic antigen. J Biol Chem. 1983; 11:7213-7222
18 Hatakeyama K, Wakabayashi-Nakao K, Ohsima K, et al. Novel protein isoforms of carcinoembryonic antigen are secreted from pancreatic, gastric and colorectal cancer cells. BMC Res Notes. 2013; 6: 381.
19 Hiroshima Y, Maawy A, Zhang Y, et al. Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Ann Surg Oncol. 2015; 22 Suppl 3: S1469-1474.
20 Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. Cancer. 1978; 42: 1399-1405.
21 Gomes C, Almeida A, Barreira A, et al. Carcinoembryonic antigen carrying SLe(X) as a new biomarker of more aggressive gastric arcinomas. Theranostics. 2019; 9: 7431-7446.
22 Saeland E, Belo AI, Mongera S, van Die I, Meijer GA, van Kooyk Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer. 2012; 131: 117-128.
23 Nolfi D, Capone A, Rosati F, Della Giovampaola C. The alpha-1,2 fucosylated tubule system of DU145 prostate cancer cells is derived from a partially fragmented Golgi complex and its formation is actin-dependent. Exp Cell Res. 2020; 396: 112324.
24 Keeley TS, Yang S, Lau E. The Diverse Contributions of Fucose Linkages in Cancer. Cancers (Basel). 2019; 11.
25 Keeley T, Lin S, Lester DK, Lau EK, Yang S. The fucose salvage pathway inhibits invadopodia formation and extracellular matrix degradation in melanoma cells. PLoS One. 2018; 13: e0199128.
26 Hotta H, Hamamura K, Yamashita K, et al. Lewis y antigen is expressed in oral squamous cell carcinoma cell lines and tissues, but disappears in the invasive regions leading to the enhanced malignant properties irrespective of sialyl-Lewis x. Glycoconj J. 2013; 30: 585-597.
27 Chandrasekaran EV, Xue J, Piskorz C, et al. Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of alpha1,2-fucosyltransferase activities. J Cancer Res Clin Oncol. 2007; 133: 599-611.
28 Huthinson WL, Du MQ, Johnson PJ, Wiliams R. Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis. Hepatology. 1991; 13: 683-688.
29 Tan KP, Ho MY, Cho HC, Yu J, Hung JT, Yu AL. Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal positioning and autophagic flux of breast cancer cells. Cell Death Dis. 2016; 7: e2347.
30 Hao Y, Zhu L, Yan L, et al. c-Fos mediates alpha1, 2- fucosyltransferase 1 and Lewis y expression in response to TGF-beta1 in ovarian cancer. Oncol Rep. 2017; 38: 3355-3366.
31 Li FF, Liu JJ, Liu DW, et al. Lewis Y regulates signaling molecules of the transforming growth factor beta pathway in ovarian carcinoma- derived RMG-I cells. Int J Oncol. 2012; 40: 1196-1202.
32 Kosanovic MM, Jankovic MM. Sialylation and fucosylation of cancer-associated prostate specific antigen. J BUON. 2005; 10: 247-250.
33 Lai TY, Chen IJ, Lin RJ, et al. Fucosyltransferase 1 and 2 play pivotal roles in breast cancer cells. Cell Death Discov. 2019; 5: 74.
34 Aubert M, Panicot L, Crotte C, Giber P, Lombardo D, et al. Restoration of alpha (1,2) fucosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells. Cancer Res. 2000; 60: 1449-1456.
35 Sousa AR, Oliveira MJ, Sarmento B. Impact of CEA-targeting Nanoparticles for Drug Delivery in Colorectal Cancer. J Pharmacol Exp Ther. 2019; 370: 657-670.
36 Dotan E, Cohen SJ, Statodub AN, Lieu CH, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35: 3338-3346.
37 Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA (+) Metastatic Colorectal Cancers. Mol Ther. 2017; 25: 1248-1258.
38 Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999; 9: 67-81.
39 Watanabe T, Kakuta J, Saito S, et al. Monoclonal antibodies specific for podocalyxin expressed on human induced pluripotent stem cells. Biochem Biophys Res Commun. 2020; 532: 647-654.